Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma

BACKGROUND/AIMS: Lenvatinib was recently proven to be non-inferior to sorafenib in treating unresectable hepatocellular carcinoma (HCC) in a phase-3 randomized controlled trial. In this study, we investigated whether the response to lenvatinib was affected by tumor immunogenicity. METHODS: Between M...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Pil Soo, Cho, Sung Woo, Lee, Jaejun, Yang, Hyun, Jang, Jeong Won, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Liver Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035673/
https://www.ncbi.nlm.nih.gov/pubmed/37384325
http://dx.doi.org/10.17998/jlc.20.2.128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035673/
https://www.ncbi.nlm.nih.gov/pubmed/37384325
http://dx.doi.org/10.17998/jlc.20.2.128

Ejemplares similares